Essentials
• Differences in sensitivity to factor VII (FVII) have been suggested between thromboplastins.
• FVII-induced International Normalized Ratio (INR) changes differ between commercial reagents.
• Recombinant human thromboplastins are more sensitive to FVII than tissue-extract thromboplastins.
• Thromboplastin choice may affect FVII-mediated INR stability.
Summary. Background: Differences regarding sensitivity to factor VII have been suggested for recombinant human and tissue-extract thromboplastins used for International Normalized Ratio (INR) measurement, but the evidence is scarce. Differences in FVII sensitivity are clinically relevant, as they can affect INR stability during treatment with vitamin K antagonists (VKAs). Objectives: To determine whether commercial thromboplastins react differently to changes in FVII. Methods: We studied the effect of addition of FVII on the INR in plasma by using three tissue-extract (Neoplastin C1+, Hepato Quick, and Thromborel S) and three recombinant human (Recombiplastin 2G, Innovin, and CoaguChek XS) thromboplastins. Three different concentrations of purified human FVII (0.006, 0.012 and 0.062 lg mL À1 plasma), or buffer, were added to five certified pooled plasmas of patients using VKAs (INR of 1. 
Introduction
Millions of people worldwide are currently treated with vitamin K antagonists (VKAs) for the primary or secondary prevention of arterial and venous thrombosis. Furthermore, VKAs will remain the anticoagulants of choice in selected patients, such as those with mechanical heart valve prostheses or with a contraindication to direct oral anticoagulants [1] . Treatment with VKAs requires monitoring via the International Normalized Ratio (INR), which is a ratio of the patient's prothrombin time (PT) to the mean PT of healthy individuals, raised to the power of the International Sensitivity Index (ISI) of the thromboplastin reagent and instrument used [2] . During VKA treatment, the INR fluctuates because of several endogenous and exogenous factors, such as an intercurrent illness, use of an interacting comedication, and food intake [3] . A previous study by Solvik et al. has shown that INR variability during VKA treatment can largely be explained by the (residual) activity of clotting factor VII and, to a lesser extent, to plasma levels of FII and FX [4] . In addition, FVII, the clotting factor with the shortest half-life, of~6 h, fluctuates more than FII and FX during treatment, and the magnitude of its fluctuation also depends on the half-life of the VKA used [5] . Pronounced fluctuations have been observed in patients using the short-acting acenocoumarol, in contrast to minimal fluctuations in patients using the long-acting phenprocoumon [5] . The activity of FVII is usually determined with bioassays that use FVII-deficient plasmas and tissue factor (thromboplastin) preparations. It has been shown that the sensitivity of the FVII assay system depends on the origin of the thromboplastin; human (placenta-derived) thromboplastin was more sensitive than rabbit thromboplastin [6] . Other investigators have reported that recombinant human tissue factor is more sensitive to FVII deficiency than other thromboplastin reagents [7, 8] . Differences in sensitivity to FVII between recombinant human and tissue-extract thromboplastins used for INR measurement have also been suggested as a source of INR inconsistency, especially during unstable anticoagulation, such as in the initial phase of oral anticoagulant therapy [9, 10] . If present, these differences in sensitivity to FVII could have a significant effect on the INR, and may explain INR discrepancies between methods reported in prior studies [9] [10] [11] [12] . More importantly, differences in sensitivity to FVII could also directly influence the requirement for VKA dose adjustment, if significant INR discrepancies are present, especially in patients using short-acting VKAs [9] [10] [11] . The conditions of a bioassay that is specific for FVII are different from those for INR measurement in samples of patients treated with VKAs. The purpose of the present study was to determine whether thromboplastins from different sources (e.g. tissue-extract or recombinant human) used in the diagnostic laboratory react differently to a fixed increase in FVII. To do this, we measured the INR change in plasma from patients using VKAs, induced by spiking the plasma with FVII. We added purified human FVII to patients' plasma, and determined the INR change by using six different commercially available thromboplastin reagents.
Materials and methods
Five commercially available thromboplastin reagents were used: Dade Innovin and Thromborel S (Siemens Healthcare Diagnostics Products, Marburg, Germany), STA Hepato Quick and Neoplastin C1+ (Diagnostica Stago, Asni eres-sur-Seine, France), and Recombiplastin 2G (Instrumentation Laboratory Company, Bedford, MA, USA). Plasma PTs were determined in polystyrene tubes with a semi-automatic coagulometer (H. Amelung, Lemgo, Germany), according to Schnitger and Gross [13] . Each PT was determined in duplicate on the same coagulometer, and the average of the two duplicates was used for further calculations. In addition, PTs were also determined with the CoaguChek XS PT Test system, which contains recombinant human thromboplastin (Roche Diagnostics, Mannheim, Germany) [14] .
Six certified deep-frozen pooled citrated plasmas were used for the experiments. Of these, one had been prepared by pooling plasmas obtained from 35 healthy individuals. The pooled normal plasma sample was used in the FVII assay to quantify the change in FVII activity after spiking with FVII. Each of the other plasmas had been prepared by pooling~200 plasmas obtained from patients treated with VKAs. Individual patients' plasmas were selected according to their INR as determined by the Leiden Anticoagulant Clinic, and pooled in the following INR intervals: 1.5-2.0, 2.0-2.4, 2.4-2.8, 2.8-3.2, and 3.2-3.6. The pooled plasmas had been stored in 0.5-mL aliquots at À 70°C. All plasmas were thawed for 3 min in a water bath at 37°C before use. Certified PTs and INRs of these plasmas had been determined by three laboratories using the international standards for rabbit thromboplastin (RBT/05) and for recombinant human thromboplastin (rTF/09), according to procedures described previously [15] . PTs for the international standards were determined with the manual (tilt-tube) technique in a water bath at 37°C. Certified INRs were calculated by use of the ISI values established for the international standards [16, 17] . The certified INRs were used to calculate instrument-specific ISI and mean normal PT (MNPT) values for the above-mentioned commercial thromboplastins [15] . Briefly, logarithms of certified INRs were plotted versus logarithms of PTs determined with the commercial thromboplastin, and an orthogonal regression line was calculated. The ISI and MNPT were calculated from the slope and intercept of the orthogonal regression line [15] .
Purified FVII (origin: human blood) was obtained from Haematologic Technologies (Essex Junction, VT, USA with Neoplastin C1+, the increase in FVII activity was 20% (median change of 20.0%, IQR 17.0-21.0). Considering all five samples of patients using VKAs, the absolute increase in FVII activity was significantly greater when measured with Recombiplastin 2G than when measured with Neoplastin C1+ (P = 0.043).
INR change after FVII addition determined with different commercial thromboplastins
Imprecision coefficients of variation for duplicate INR measurement with the coagulometer according to Schnitger and Gross were 0.6% (Hepato Quick), 1.3% (Innovin), 1.7% (Neoplastin C1+), 2.3% (Thromborel S), and 4.5% (Recombiplastin 2G), respectively. The coefficient of variation for the calculated CoaguChek XS INR results was 3.4%. PTs shortened and INR values decreased with the addition of increasing FVII concentrations in all five pooled plasmas of patients using VKAs, irrespective of the thromboplastin reagent used (Fig. 1) . Mean PT and mean INR results of each plasma sample of patients using VKAs, after the addition of different concentrations of FVII or buffer, are also shown in Table S1 for all reagent systems. Absolute and relative INR changes after addition of FVII increased with increasing INR level, independently of the administered FVII concentration or the reagent system used (Fig. 1) . The median proportional INR changes and IQRs for the different reagents after spiking with FVII were À 13.5% (À 26.7 to À 7.8) (Recombiplastin 2G), À 11.9% (À 19.3 to À 7.3) (Innovin), À 11.9% (À 19.9 to À 7.4) (CoaguChek XS), À 10.3% (À 17.3 to À 9.0) (Thromborel S), À 10.2% (À 17.4 to À 7.3) (Neoplastin C1+), and À 9.1% (À 17.0 to À 6.0) (Hepato Quick). Overall, there were significant differences (P < 0.001) between the six thromboplastins regarding the relative change in INR after FVII addition (Fig. 2) . In contrast, no differences were observed among the recombinant human (P = 0.085) or tissue-extract (P = 0.575) thromboplastins (Fig. 2) . After the data of the three recombinant human and three tissue-extract thromboplastins had been combined, the relative INR changes as measured with the recombinant human thromboplastins were significantly higher (P < 0.001) than the INR changes as measured with the tissue-extract thromboplastins (Fig. 3) .
Discussion
In our study, we found that, despite optimal calibration, the relative INR change after FVII addition significantly differed between the six thromboplastin reagents used for INR measurement of patients using VKAs. One of these thromboplastins was used in an electrochemical point-ofcare device, and the other five were used in a mechanical coagulometer. Furthermore, the INR change after FVII addition was greater when measured with a recombinant human thromboplastin than when measured with a tissue-extract thromboplastin, suggesting higher sensitivity of recombinant human thromboplastins to FVII. Our findings are in agreement with previous results from Smith et al. [19] . In their study, recombinant human thromboplastins (Innovin and Recombiplastin 2G) were more sensitive to FVII deficiency than tissue-extract thromboplastins (Thromborel S and Neoplastin C1+) [19] . However, as stated by these authors, differences regarding FVII sensitivity, as measured in FVII-deficient plasma, cannot be directly extrapolated to patients using VKAs, as FII and FX levels are also decreased in these patients. As in our study, Smith et al. also added purified human FVII to plasma of patients using VKAs, but only reported the change in PT measured in individual patient plasmas with synthetic non-commercially available thromboplastins, which complicates the translation to clinical practice. Differences regarding FVII sensitivity between reagents are of clinical importance, as it has been shown that patients monitored with the tissue-extract thromboplastin Hepato Quick achieve better anticoagulation control than those monitored with the recombinant human thromboplastins Innovin and Recombiplastin 2G [20] . Furthermore, in a previous study, we reported a significant difference in the percentage of time in therapeutic range between patients monitored with a laboratory method using Hepato Quick and patients monitored by professionals with the CoaguChek XS point-of-care system [21] . The fact that most patients in the Netherlands [19] , and in the previously mentioned cohort study [21] , are treated with the short-acting VKA acenocoumarol may help to explain the observed differences in anticoagulation control between patients monitored with reagents from different sources. Circulating FVII levels can fluctuate strongly in these patients, and recombinant human thromboplastins seem to be very sensitive to changes in FVII, thus directly affecting the measured INR stability [5, 22] . However, method-dependent or reagent-dependent differences in INR stability have also been reported in patients using the longer-acting warfarin, emphasizing the importance of our findings beyond patients treated with acenocoumarol [4, 23] . It has been suggested that the pharmacodynamic effects of warfarin regarding INR variability are more similar to those of acenocoumarol than to those of phenprocoumon [24] . Also, similar daily FVII fluctuations have been observed in patients using warfarin and those using acenocoumarol [25] . Clinicians should be aware of these reagent-dependent differences regarding INR stability, and include this knowledge in their evaluation of the quality of anticoagulation control in their patients. However, it should be noted that reagent-dependent differences in anticoagulation control have not yet been directly translated into higher thrombotic or bleeding complication rates between patients in these studies [21, 23] . Therefore, there is currently no direct requirement to switch to a specific thromboplastin or monitoring method.
Strengths and limitations
We used pooled patients' plasmas for our experiments rather than individual patient plasmas. Pooled patients' plasmas have the advantage that differences between individuals in clotting factor concentrations are averaged. In pooled plasmas, the relationship between the INR and clotting factor activity is less variable than the same relationship determined in individual patient plasmas [26] . The influence on the INR of a given dose of FVII added to pooled plasma is therefore more representative than that of the same dose added to a plasma sample of an individual patient. In an individual patient's plasma, there is a greater probability that an INR change is also influenced by variation in other clotting factors. A limitation of our study is that we used citrated plasma for the CoaguChek XS measurements. CoaguChek XS was designed for non-citrated whole blood rather than for recalcified citrated plasma. Ideally, the sensitivity of CoaguChek XS to FVII should be investigated by adding purified FVII to non-citrated whole blood. However, it should be mentioned that the INRs for recalcified pooled plasmas read from the screen of CoaguChek XS were similar to the certified INR values determined with the international standard thromboplastins by use of the manual tilt-tube method. Furthermore, in another study, the overall paired values of recalcified plasma INR values from CoaguChek XS and a laboratory INR method showed good correlation [27] . Good agreement between certified INR and CoaguChek XS values for recalcified plasmas has also been observed in an external quality assessment scheme [28] . These findings indicate that recalcified plasma is an acceptable substitute for whole blood for INR measurement with CoaguChek XS. Another limitation of our study is that we do not know the exact phospholipid composition of the thromboplastins used in our study. It was stated by Smith et al. that the differences in sensitivity to FVII between tissuederived and recombinant human thromboplastins can be explained by differences in phospholipid composition between reagents, and that the dissimilar sensitivities to FVII may become more apparent when clotting factor deficiencies become more severe [19] . However, even if we knew the exact phospholipid compositions of the commercial reagents, they would still be different from the compositions used by Smith et al., thus hampering a direct comparison. Alternatively, the apparent difference in FVII activity between recombinant and tissue-derived thromboplastins (Table 1 ) might be explained by the influence of other factors present in the plasma of patients using VKAs. It has been suggested that rabbit thromboplastin is not sensitive to non-carboxylated protein induced by VKA (PIVKA), whereas clotting induced by human thromboplastin can be inhibited by PIVKA [29] . Inhibition of clotting by PIVKA might reduce the apparent FVII activity measured with recombinant human thromboplastin. Our findings suggest that knowledge of the thromboplastin source (recombinant human or tissue-derived) helps to predict factor FVII sensitivity. Apart from the above-mentioned possible explanations, another explanation for differences in FVII sensitivity between recombinant human and tissue-extract thromboplastins could be that tissue-derived thromboplastins may be contaminated with traces of FVII and activated FVII (FVIIa) [22] . It was previously shown that, when traces of FVIIa were added to recombinant human thromboplastins, sensitivity to FVII decreased [22] . Furthermore, significant differences regarding FVII sensitivity have been reported between tissue-derived thromboplastins from normal and FVII-deficient animals, also suggesting FVII contamination as an explanation for differences in FVII sensitivity between thromboplastins [22, 30] .
In conclusion, we found significant differences in sensitivity to FVII between commercially available thromboplastin reagents used for INR measurement in patients using VKAs. These differences in sensitivity to FVII can explain INR discrepancies between methods reported in prior studies and observations of differences regarding anticoagulation control between patients monitored with thromboplastins from different sources. 
